Gamma-hydroxybutyrate is an endogenous Gamma-hydroxybutyrate is an endogenous fatty acid found in every cell in the human fatty acid found in every cell in the human body. In the brain it is widely distributed, body. In the brain it is widely distributed, reaching highest concentrations in the hyreaching highest concentrations in the hypothalamus and basal ganglia (Gallimberti pothalamus and basal ganglia (Gallimberti et al et al, 1989) . It is available as a liquid or , 1989) . It is available as a liquid or in powdered form and when taken by in powdered form and when taken by mouth it readily enters the brain and mouth it readily enters the brain and produces behavioural consequences that produces behavioural consequences that include anxiolytic, sedative and euphoric include anxiolytic, sedative and euphoric effects. It appears to have complex effects effects. It appears to have complex effects on both GABA on both GABA A A and GABA and GABA B B receptors receptors and has some actions similar to benzodiazeand has some actions similar to benzodiazepines, baclofen and alcohol (Barbaccia pines, baclofen and alcohol (Barbaccia et al et al, , 2002) . The effects may result from poten-2002) . The effects may result from potentiation of cerebral dopaminergic systems tiation of cerebral dopaminergic systems and there is evidence that the serotonin sysand there is evidence that the serotonin system also may be involved via stimulation of tem also may be involved via stimulation of tissue serotonin turnover due to an increase tissue serotonin turnover due to an increase in tryptophan transport (Gobaille in tryptophan transport (Gobaille et al et al, , 2002) . Gamma-hydroxybutyrate has been 2002). Gamma-hydroxybutyrate has been utilised in medical settings for a number utilised in medical settings for a number of years to induce anaesthesia (Laborit, of years to induce anaesthesia (Laborit, 1964) , to aid with alcohol dependence 1964), to aid with alcohol dependence and opioid withdrawal (Kam & Yoong, and opioid withdrawal (Kam & Yoong, 1998; Tarricone, 2000; Nicholson & 1998; Tarricone, 2000; Nicholson & Balster, 2001 ) and as a treatment for sleep Balster, 2001 ) and as a treatment for sleep disorders (Mamelak, 1989; Chin disorders (Mamelak, 1989; Chin et al et al, , 1992) . 1992).
LEGAL STATUS LEGAL STATUS
During the 1980s GHB was popular in the During the 1980s GHB was popular in the USA as an over-the-counter food USA as an over-the-counter food supplement. It enjoyed popularity among supplement. It enjoyed popularity among bodybuilders because it was believed to bodybuilders because it was believed to aid in fat reduction and muscle building aid in fat reduction and muscle building (Miotto (Miotto et al et al, 2001) . Gamma-hydroxybuty-, 2001 ). Gamma-hydroxybutyrate stimulates growth hormone release and rate stimulates growth hormone release and activates the 'pentose pathway', which activates the 'pentose pathway', which plays an important role in the synthesis of plays an important role in the synthesis of protein within the body. It also results in protein within the body. It also results in a protein-sparing effect, which reduces the a protein-sparing effect, which reduces the rate at which the body breaks down its rate at which the body breaks down its own proteins and it is these properties that own proteins and it is these properties that are believed to underlie its ability to aid in are believed to underlie its ability to aid in bodybuilding and fat loss (Miotto bodybuilding and fat loss (Miotto et al et al, , 2001 ). In 1990 the Food and Drug Admin-2001) . In 1990 the Food and Drug Administration banned over-the-counter sales istration banned over-the-counter sales because of the growing body of evidence because of the growing body of evidence of the potential for misuse. This was of the potential for misuse. This was followed in March 2000 by the placing of followed in March 2000 by the placing of the substance in Schedule 1, making it the substance in Schedule 1, making it illegal to possess or sell GHB without a illegal to possess or sell GHB without a licence in the USA. At the moment in the licence in the USA. At the moment in the UK possession of GHB is not illegal, but UK possession of GHB is not illegal, but manufacture and supply is illegal because manufacture and supply is illegal because the drug is a controlled substance under the drug is a controlled substance under the Medicines Act 1968. (2003) , in a study of 76 Australian users, report that reasons for using the drug users, report that reasons for using the drug recreationally include the resultant feelings recreationally include the resultant feelings of euphoria, relaxation, increased sociabilof euphoria, relaxation, increased sociability and loss of inhibition, as well as heightity and loss of inhibition, as well as heightened sexual interest. There has been very ened sexual interest. There has been very little UK-based research into the use of little UK-based research into the use of GHB. One survey (Winstock GHB. One survey (Winstock et al et al, 2001) , 2001) reports that 13% of a sample of 1151 reports that 13% of a sample of 1151 respondents recruited via a dance-culture respondents recruited via a dance-culture magazine (mean age of 23.9 years) reported magazine (mean age of 23.9 years) reported using the drug. The mean age of first use of using the drug. The mean age of first use of GHB in this sample was 22.4 years. The GHB in this sample was 22.4 years. The effects of GHB were reported as including effects of GHB were reported as including feelings of relaxation, a sense of well-being feelings of relaxation, a sense of well-being and very restful sleep, and its use is and very restful sleep, and its use is frequently associated with 'rave' or frequently associated with 'rave' or 'dance-party' settings, where it is used to 'dance-party' settings, where it is used to aid 'comedown' following the use of stimuaid 'comedown' following the use of stimulants. Consequently it is often taken along lants. Consequently it is often taken along with or following the use of a range of with or following the use of a range of other substances, including, most other substances, including, most frequently, methylenedioxymethamphetafrequently, methylenedioxymethamphetamine (MDMA, Ecstasy), cocaine, lysergic mine (MDMA, Ecstasy), cocaine, lysergic acid diethylamide (LSD), cannabis and acid diethylamide (LSD), cannabis and alcohol (Teter & Guthrie, 2001; Degenalcohol (Teter & Guthrie, 2001; Degenhardt hardt et al et al, 2002; Tong & Boyer, 2002) . , 2002; Tong & Boyer, 2002) . Although interactions with other drugs of Although interactions with other drugs of misuse are as yet unclear, research indicates misuse are as yet unclear, research indicates that the concomitant use of alcohol interthat the concomitant use of alcohol interferes with GHB metabolism, preventing feres with GHB metabolism, preventing breakdown, raising blood concentrations breakdown, raising blood concentrations and making respiratory arrest more likely and making respiratory arrest more likely (Karch (Karch et al et al, 2001 ). In the USA, GHB is , 2001). In the USA, GHB is popular among gay and bisexual men popular among gay and bisexual men where it has been associated with increased where it has been associated with increased sexual risk (Colfax sexual risk ( 
ACUTE SIDE-EFFECTS ACUTE SIDE-EFFECTS
The increasing popularity of GHB is The increasing popularity of GHB is indicated by a sharp rise in the number of indicated by a sharp rise in the number of accident and emergency cases associated accident and emergency cases associated with it across Europe and in the USA with it across Europe and in the USA (Espinosa (Espinosa et al overdose. Gamma-hydroxybutyrate is rapidly metaGamma-hydroxybutyrate is rapidly metabolised into carbon dioxide and water with bolised into carbon dioxide and water with no residue of toxic metabolites detectable no residue of toxic metabolites detectable in urine 4-5 h after ingestion (Laborit, in urine 4-5 h after ingestion (Laborit, 1964) . Consequently this makes it difficult 1964). Consequently this makes it difficult to detect use of the substance during to detect use of the substance during routine drug screens or following emerroutine drug screens or following emergency admission. gency admission.
TOLER ANCE TOLER ANCE AND WITHDRAWAL AND WITHDR AWAL
There is evidence that users develop There is evidence that users develop tolerance to and physical dependence on tolerance to and physical dependence on GHB. Animal studies provide evidence for GHB. Animal studies provide evidence for the development of tolerance and the the development of tolerance and the presence of reinforcing/rewarding properpresence of reinforcing/rewarding properties (Itzhak & Ali, 2002) . In humans a ties (Itzhak & Ali, 2002) . In humans a GHB withdrawal syndrome is reported to GHB withdrawal syndrome is reported to include insomnia, anxiety, tremor, coninclude insomnia, anxiety, tremor, confusion, delirium, hallucinations, tachyfusion, delirium, hallucinations, tachycardia, hypertension, nausea, vomiting cardia, hypertension, nausea, vomiting and diaphoresis (Galloway and diaphoresis ( (2003) report two cases of severe withdrawal delirium on a psychiatric unit in the wal delirium on a psychiatric unit in the USA. It is likely that, as the use of the drug USA. It is likely that, as the use of the drug increases, the psychiatric profession will increases, the psychiatric profession will have a greater role to play in the managehave a greater role to play in the management of the consequences of use. Owing ment of the consequences of use. Owing to its short duration of action, with a to its short duration of action, with a half-life of only 1-2 h (Scrima half-life of only 1-2 h (Scrima et al et al, 1990) , 1990) and rapid elimination (Palatini and rapid elimination (Palatini et al et al, , 1993) , withdrawal symptoms appear ra-1993), withdrawal symptoms appear rapidly following last administration (within pidly following last administration (within 1-6 h) and can persist for a number of 1-6 h) and can persist for a number of weeks. Price (2000) reports the case of a weeks. Price (2000) reports the case of a 43-year-old male user who had been taking 43-year-old male user who had been taking GHB for just over 2 years prior to referral GHB for just over 2 years prior to referral for detoxification. The patient reported for detoxification. The patient reported that over the period of use he had doubled that over the period of use he had doubled his dosage and increased the frequency of his dosage and increased the frequency of ingestion from 15 ml taken irregularly to ingestion from 15 ml taken irregularly to 30 ml every 3 h in order to obtain the 30 ml every 3 h in order to obtain the desired psychoactive effects. Withdrawal desired psychoactive effects. Withdrawal symptoms were described as including ansymptoms were described as including anxiety, panic attacks and feelings of terror xiety, panic attacks and feelings of terror coupled with tremor and some autonomic coupled with tremor and some autonomic features, for example diarrhoea. Detoxififeatures, for example diarrhoea. Detoxification was undertaken on an in-patient cation was undertaken on an in-patient basis and involved a diazepam-reducing basis and involved a diazepam-reducing regime over a period of 11 days. In a similar regime over a period of 11 days. In a similar 
USE OF PRECURSORS USE OF PRECURSORS
There is now evidence that, as the legal There is now evidence that, as the legal status of GHB changes, users may turn status of GHB changes, users may turn to the use of precursors such as gammato the use of precursors such as gammabutyrolactone (GBL) and 1,4-butanediol. butyrolactone (GBL) and 1,4-butanediol. These precursors, which remain widely These precursors, which remain widely available via the internet, are metabolised available via the internet, are metabolised to GHB and pose the same risks to the user. to GHB and pose the same risks to the user. Schneir Schneir et al et al (2001) report a case of with-(2001) report a case of withdrawal from GBL and 1,4-butanediol. The drawal from GBL and 1,4-butanediol. The symptoms reported were nearly identical symptoms reported were nearly identical to those for GHB withdrawal and included to those for GHB withdrawal and included hallucinations, tachycardia, tremor, nystaghallucinations, tachycardia, tremor, nystagmus and diaphoresis. In a similar report mus and diaphoresis. In a similar report Sivilotti Sivilotti et al et al (2001) give data from five pa- (2001) give data from five patients who presented with severe GBL withtients who presented with severe GBL withdrawal syndrome that included paranoid drawal syndrome that included paranoid delusions, hallucinations, psychosis and delusions, hallucinations, psychosis and autonomic instability. Initial treatment autonomic instability. Initial treatment with lorazepam proved to be ineffective, with lorazepam proved to be ineffective, but subsequent treatment with pentobarbibut subsequent treatment with pentobarbitol resulted in good recovery within 5 days. tol resulted in good recovery within 5 days. In the UK reports of misuse and withdrawal In the UK reports of misuse and withdrawal from these precursors should be expected. from these precursors should be expected.
MODE OF ACTION MODE OF ACTION
The physiological mechanisms for withThe physiological mechanisms for withdrawal from GHB are not clearly underdrawal from GHB are not clearly understood. Research indicates that chronic use stood. Research indicates that chronic use of GHB results in a down-regulation of of GHB results in a down-regulation of inhibitory GABA inhibitory GABA A A and GABA and GABA B B and GHB and GHB receptors, resulting in the development of receptors, resulting in the development of tolerance (Snead & Nichols, 1987; Hechler tolerance (Snead & Nichols, 1987; Hechler et al et al, 1997) . Cessation or a decrease in , 1997). Cessation or a decrease in GHB use then results in a disinhibition of GHB use then results in a disinhibition of excitatory neurotransmitters (glutamate, excitatory neurotransmitters (glutamate, norepinephrine and dopamine) and leads norepinephrine and dopamine) and leads to withdrawal symptomatology. Similarito withdrawal symptomatology. Similarities in terms of the psychoactive properties ties in terms of the psychoactive properties of use and of the pathophysiological effects of use and of the pathophysiological effects of withdrawal have been reported between of withdrawal have been reported between GHB and benzodiazepines (Miotto & GHB and benzodiazepines (Miotto & Roth, 2001 ). This suggests a common Roth, 2001 ). This suggests a common mechanism of action and Miotto & Roth mechanism of action and Miotto & Roth Their results indicate that the sedative/hypnotic effects of GHB result sedative/hypnotic effects of GHB result from activation of GABA from activation of GABA B B receptors and receptors and that the behavioural depression of GHB that the behavioural depression of GHB was similar to that produced by baclofen, was similar to that produced by baclofen, a GABA a GABA B B agonist. In addition, the effect agonist. In addition, the effect of both drugs was completely prevented of both drugs was completely prevented by the administration of specific GABA by the administration of specific GABA B B antagonists SCH 50911 and CGP 46381. antagonists SCH 50911 and CGP 46381.
SUMMARY SUMMARY
Gamma-hydroxybutyrate misuse is a Gamma-hydroxybutyrate misuse is a relatively recent phenomenon and one that relatively recent phenomenon and one that is far from clearly understood in terms of is far from clearly understood in terms of the likely cost to the user and to the wider the likely cost to the user and to the wider community. There have been no systematic community. There have been no systematic studies of the prevalence of dependency on studies of the prevalence of dependency on GHB in the UK, nor do we have sufficient GHB in the UK, nor do we have sufficient information relating to the demographic information relating to the demographic characteristics or the patterns of drug use characteristics or the patterns of drug use among GHB users in this country. In among GHB users in this country. In addition, the mechanisms underlying the addition, the mechanisms underlying the development of tolerance to and the development of tolerance to and the rewarding effects of GHB, as well as any rewarding effects of GHB, as well as any possible interaction effects with other possible interaction effects with other drugs, are poorly understood. Similarly, drugs, are poorly understood. Similarly, although research has clearly demonstrated although research has clearly demonstrated the acute risks of use, we know very little the acute risks of use, we know very little about long-term emotional, neuropsychoabout long-term emotional, neuropsychological and behavioural costs. It is likely, logical and behavioural costs. It is likely, however, that as use of the drug and its prehowever, that as use of the drug and its precursors increases in the UK the psychiatric cursors increases in the UK the psychiatric profession increasingly will be faced with profession increasingly will be faced with individuals experiencing the adverse effects individuals experiencing the adverse effects of use and withdrawal. What is clear from of use and withdrawal. What is clear from the research so far is that misuse of GHB the research so far is that misuse of GHB places the individual and the wider complaces the individual and the wider community at significant risk. Further studies munity at significant risk. Further studies of the use and misuse of this potentially of the use and misuse of this potentially harmful substance are clearly needed. harmful substance are clearly needed.
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